Review



sensolyte 390 ace2 activity assay kit  (AnaSpec)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    AnaSpec sensolyte 390 ace2 activity assay kit
    Soluble <t>ACE2</t> (sACE2) activity in sera from unexposed pre‐pandemic controls ( n = 154) and (A) participants 3 months ( n = 1192) and 1 year ( n = 345) after SARS‐CoV‐2 exposure, (B) categorized by participants with ( n = 594) and without ( n = 598) evidence of infection 3 months after exposure, and (D) categorized by participants with ( n = 236) and without ( n = 109) evidence of infection 12 months after exposure. (C) Longitudinal sACE2 activity from 345 participants 3−12 months after SARS‐CoV‐2 exposure. Individual data for each participant are depicted in gray. (A, B, D) Mean and 1 ± times standard deviation and (C) longitudinal mean are shown in black. p values were calculated using (A, B, D) one‐way ANOVA (A: F [2, 1688] = 184.4, p < 0.0001; B: F [2, 1343] = 61.9, p < 0.0001; D: F (2, 496) = 0.33, p = 0.72) with Tukey correction for multiple comparisons and (C) paired t ‐test.
    Sensolyte 390 Ace2 Activity Assay Kit, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sensolyte+390+ace2+activity+kit/pmc11612704-88-10-17?v=AnaSpec
    Average 90 stars, based on 1 article reviews
    sensolyte 390 ace2 activity assay kit - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Elevated Soluble ACE2 Activity in Children and Adults After SARS‐CoV‐2 Exposure Irrespective of Laboratory‐Confirmed Infection"

    Article Title: Elevated Soluble ACE2 Activity in Children and Adults After SARS‐CoV‐2 Exposure Irrespective of Laboratory‐Confirmed Infection

    Journal: Journal of Medical Virology

    doi: 10.1002/jmv.70098

    Soluble ACE2 (sACE2) activity in sera from unexposed pre‐pandemic controls ( n = 154) and (A) participants 3 months ( n = 1192) and 1 year ( n = 345) after SARS‐CoV‐2 exposure, (B) categorized by participants with ( n = 594) and without ( n = 598) evidence of infection 3 months after exposure, and (D) categorized by participants with ( n = 236) and without ( n = 109) evidence of infection 12 months after exposure. (C) Longitudinal sACE2 activity from 345 participants 3−12 months after SARS‐CoV‐2 exposure. Individual data for each participant are depicted in gray. (A, B, D) Mean and 1 ± times standard deviation and (C) longitudinal mean are shown in black. p values were calculated using (A, B, D) one‐way ANOVA (A: F [2, 1688] = 184.4, p < 0.0001; B: F [2, 1343] = 61.9, p < 0.0001; D: F (2, 496) = 0.33, p = 0.72) with Tukey correction for multiple comparisons and (C) paired t ‐test.
    Figure Legend Snippet: Soluble ACE2 (sACE2) activity in sera from unexposed pre‐pandemic controls ( n = 154) and (A) participants 3 months ( n = 1192) and 1 year ( n = 345) after SARS‐CoV‐2 exposure, (B) categorized by participants with ( n = 594) and without ( n = 598) evidence of infection 3 months after exposure, and (D) categorized by participants with ( n = 236) and without ( n = 109) evidence of infection 12 months after exposure. (C) Longitudinal sACE2 activity from 345 participants 3−12 months after SARS‐CoV‐2 exposure. Individual data for each participant are depicted in gray. (A, B, D) Mean and 1 ± times standard deviation and (C) longitudinal mean are shown in black. p values were calculated using (A, B, D) one‐way ANOVA (A: F [2, 1688] = 184.4, p < 0.0001; B: F [2, 1343] = 61.9, p < 0.0001; D: F (2, 496) = 0.33, p = 0.72) with Tukey correction for multiple comparisons and (C) paired t ‐test.

    Techniques Used: Activity Assay, Infection, Standard Deviation

    Soluble ACE2 (sACE2) in sera of (A) 1192 participants 3 months and (B) 345 participants 1 year after SARS‐CoV‐2 exposure stratified by sex. Mean and 1 ± times standard deviation are shown in black and individual data for each participant are depicted in gray. p values were calculated using unpaired t ‐tests.
    Figure Legend Snippet: Soluble ACE2 (sACE2) in sera of (A) 1192 participants 3 months and (B) 345 participants 1 year after SARS‐CoV‐2 exposure stratified by sex. Mean and 1 ± times standard deviation are shown in black and individual data for each participant are depicted in gray. p values were calculated using unpaired t ‐tests.

    Techniques Used: Standard Deviation

    Soluble ACE2 (sACE2) activity stratified by age group in sera of (A) 1192 participants 3 months and (B) 345 participants 1 year after SARS‐CoV‐2 exposure and participants (C) without and (D) with evidence of infection 3 months after SARS‐CoV‐2 exposure. Mean and 1 ± times standard deviation are shown in black and individual data for each participant are depicted in gray. p values were calculated using unpaired t ‐tests.
    Figure Legend Snippet: Soluble ACE2 (sACE2) activity stratified by age group in sera of (A) 1192 participants 3 months and (B) 345 participants 1 year after SARS‐CoV‐2 exposure and participants (C) without and (D) with evidence of infection 3 months after SARS‐CoV‐2 exposure. Mean and 1 ± times standard deviation are shown in black and individual data for each participant are depicted in gray. p values were calculated using unpaired t ‐tests.

    Techniques Used: Activity Assay, Infection, Standard Deviation

    (A) Soluble ACE2 (sACE2) activity in sera of 67 exposed participants without prior evidence of SARS‐CoV‐2 infection (seronegative and no positive PCR) 3 months after SARS‐CoV‐2 exposure stratified by SARS‐CoV‐2 specific T‐cell response. (B) Longitudinal sACE2 activity from 22 T‐cell negative participants 3−12 months after SARS‐CoV‐2 exposure. Individual data for each participant are shown in gray. (A) Mean and 1 ± times standard deviation and (B) longitudinal mean are shown in black. p value was calculated using (A) unpaired and (B) paired t ‐test.
    Figure Legend Snippet: (A) Soluble ACE2 (sACE2) activity in sera of 67 exposed participants without prior evidence of SARS‐CoV‐2 infection (seronegative and no positive PCR) 3 months after SARS‐CoV‐2 exposure stratified by SARS‐CoV‐2 specific T‐cell response. (B) Longitudinal sACE2 activity from 22 T‐cell negative participants 3−12 months after SARS‐CoV‐2 exposure. Individual data for each participant are shown in gray. (A) Mean and 1 ± times standard deviation and (B) longitudinal mean are shown in black. p value was calculated using (A) unpaired and (B) paired t ‐test.

    Techniques Used: Activity Assay, Infection, Standard Deviation

    (A) Schematic illustration of in vitro experiments to determine shedding of soluble ACE2 (sACE2) upon exposure to pseudovirus particles bearing a SARS‐CoV‐2 spike protein (SCoV‐2 spike) (created with BioRender.com ). (B) Absolute soluble ACE2 (sACE2) activity and the change in sACE2 (∆sACE2) activity in the supernatant of Calu‐3 (human lung) cells after 16 h of exposure to pseudovirus with (yes) versus without (no) SARS‐CoV‐2 spike. Individual data points for each biologically independent experiment are depicted with black dots connected by lines. For ∆sACE2 activity, the mean and confidence intervals between the experiments are shown. The p ‐value was calculated using a paired t ‐test.
    Figure Legend Snippet: (A) Schematic illustration of in vitro experiments to determine shedding of soluble ACE2 (sACE2) upon exposure to pseudovirus particles bearing a SARS‐CoV‐2 spike protein (SCoV‐2 spike) (created with BioRender.com ). (B) Absolute soluble ACE2 (sACE2) activity and the change in sACE2 (∆sACE2) activity in the supernatant of Calu‐3 (human lung) cells after 16 h of exposure to pseudovirus with (yes) versus without (no) SARS‐CoV‐2 spike. Individual data points for each biologically independent experiment are depicted with black dots connected by lines. For ∆sACE2 activity, the mean and confidence intervals between the experiments are shown. The p ‐value was calculated using a paired t ‐test.

    Techniques Used: In Vitro, Activity Assay



    Similar Products

    sensolyte 390 ace2 activity assay kit  (AnaSpec)
    90
    AnaSpec sensolyte 390 ace2 activity assay kit
    Soluble <t>ACE2</t> (sACE2) activity in sera from unexposed pre‐pandemic controls ( n = 154) and (A) participants 3 months ( n = 1192) and 1 year ( n = 345) after SARS‐CoV‐2 exposure, (B) categorized by participants with ( n = 594) and without ( n = 598) evidence of infection 3 months after exposure, and (D) categorized by participants with ( n = 236) and without ( n = 109) evidence of infection 12 months after exposure. (C) Longitudinal sACE2 activity from 345 participants 3−12 months after SARS‐CoV‐2 exposure. Individual data for each participant are depicted in gray. (A, B, D) Mean and 1 ± times standard deviation and (C) longitudinal mean are shown in black. p values were calculated using (A, B, D) one‐way ANOVA (A: F [2, 1688] = 184.4, p < 0.0001; B: F [2, 1343] = 61.9, p < 0.0001; D: F (2, 496) = 0.33, p = 0.72) with Tukey correction for multiple comparisons and (C) paired t ‐test.
    Sensolyte 390 Ace2 Activity Assay Kit, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sensolyte+390+ace2+activity+kit/pmc11612704-88-10-17?v=AnaSpec
    Average 90 stars, based on 1 article reviews
    sensolyte 390 ace2 activity assay kit - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    fluorimetric sensolyte 390 ace2 activity assay kit  (AnaSpec)
    90
    AnaSpec fluorimetric sensolyte 390 ace2 activity assay kit
    Soluble <t>ACE2</t> (sACE2) activity in sera from unexposed pre‐pandemic controls ( n = 154) and (A) participants 3 months ( n = 1192) and 1 year ( n = 345) after SARS‐CoV‐2 exposure, (B) categorized by participants with ( n = 594) and without ( n = 598) evidence of infection 3 months after exposure, and (D) categorized by participants with ( n = 236) and without ( n = 109) evidence of infection 12 months after exposure. (C) Longitudinal sACE2 activity from 345 participants 3−12 months after SARS‐CoV‐2 exposure. Individual data for each participant are depicted in gray. (A, B, D) Mean and 1 ± times standard deviation and (C) longitudinal mean are shown in black. p values were calculated using (A, B, D) one‐way ANOVA (A: F [2, 1688] = 184.4, p < 0.0001; B: F [2, 1343] = 61.9, p < 0.0001; D: F (2, 496) = 0.33, p = 0.72) with Tukey correction for multiple comparisons and (C) paired t ‐test.
    Fluorimetric Sensolyte 390 Ace2 Activity Assay Kit, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sensolyte+390+ace2+activity+kit/pm39349131-53-1-8?v=AnaSpec
    Average 90 stars, based on 1 article reviews
    fluorimetric sensolyte 390 ace2 activity assay kit - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    sensolyte®390 ace2 activity assay kit as-72086  (AnaSpec)
    90
    AnaSpec sensolyte®390 ace2 activity assay kit as-72086
    Inhibition of <t>ACE2</t> activity by different concentrations on MLN-4760 or HCQ. Graph shows % of inhibition for ACE2 activity in an inhibitory activity in vitro assay using different concentrations of the specific ACE2 blocker MLN-4760 (black circles) and the aminoquinoline HCQ (diamonds). n = 3‐5.
    Sensolyte®390 Ace2 Activity Assay Kit As 72086, supplied by AnaSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/sensolyte+390+ace2+activity+kit/pmc08313324-27-31-40?v=AnaSpec
    Average 90 stars, based on 1 article reviews
    sensolyte®390 ace2 activity assay kit as-72086 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Soluble ACE2 (sACE2) activity in sera from unexposed pre‐pandemic controls ( n = 154) and (A) participants 3 months ( n = 1192) and 1 year ( n = 345) after SARS‐CoV‐2 exposure, (B) categorized by participants with ( n = 594) and without ( n = 598) evidence of infection 3 months after exposure, and (D) categorized by participants with ( n = 236) and without ( n = 109) evidence of infection 12 months after exposure. (C) Longitudinal sACE2 activity from 345 participants 3−12 months after SARS‐CoV‐2 exposure. Individual data for each participant are depicted in gray. (A, B, D) Mean and 1 ± times standard deviation and (C) longitudinal mean are shown in black. p values were calculated using (A, B, D) one‐way ANOVA (A: F [2, 1688] = 184.4, p < 0.0001; B: F [2, 1343] = 61.9, p < 0.0001; D: F (2, 496) = 0.33, p = 0.72) with Tukey correction for multiple comparisons and (C) paired t ‐test.

    Journal: Journal of Medical Virology

    Article Title: Elevated Soluble ACE2 Activity in Children and Adults After SARS‐CoV‐2 Exposure Irrespective of Laboratory‐Confirmed Infection

    doi: 10.1002/jmv.70098

    Figure Lengend Snippet: Soluble ACE2 (sACE2) activity in sera from unexposed pre‐pandemic controls ( n = 154) and (A) participants 3 months ( n = 1192) and 1 year ( n = 345) after SARS‐CoV‐2 exposure, (B) categorized by participants with ( n = 594) and without ( n = 598) evidence of infection 3 months after exposure, and (D) categorized by participants with ( n = 236) and without ( n = 109) evidence of infection 12 months after exposure. (C) Longitudinal sACE2 activity from 345 participants 3−12 months after SARS‐CoV‐2 exposure. Individual data for each participant are depicted in gray. (A, B, D) Mean and 1 ± times standard deviation and (C) longitudinal mean are shown in black. p values were calculated using (A, B, D) one‐way ANOVA (A: F [2, 1688] = 184.4, p < 0.0001; B: F [2, 1343] = 61.9, p < 0.0001; D: F (2, 496) = 0.33, p = 0.72) with Tukey correction for multiple comparisons and (C) paired t ‐test.

    Article Snippet: Plasma sACE2 enzyme activity was determined using the commercially available SensoLyte 390 ACE2 activity assay kit (72086; AnaSpec) according to the manufacturer's protocol.

    Techniques: Activity Assay, Infection, Standard Deviation

    Soluble ACE2 (sACE2) in sera of (A) 1192 participants 3 months and (B) 345 participants 1 year after SARS‐CoV‐2 exposure stratified by sex. Mean and 1 ± times standard deviation are shown in black and individual data for each participant are depicted in gray. p values were calculated using unpaired t ‐tests.

    Journal: Journal of Medical Virology

    Article Title: Elevated Soluble ACE2 Activity in Children and Adults After SARS‐CoV‐2 Exposure Irrespective of Laboratory‐Confirmed Infection

    doi: 10.1002/jmv.70098

    Figure Lengend Snippet: Soluble ACE2 (sACE2) in sera of (A) 1192 participants 3 months and (B) 345 participants 1 year after SARS‐CoV‐2 exposure stratified by sex. Mean and 1 ± times standard deviation are shown in black and individual data for each participant are depicted in gray. p values were calculated using unpaired t ‐tests.

    Article Snippet: Plasma sACE2 enzyme activity was determined using the commercially available SensoLyte 390 ACE2 activity assay kit (72086; AnaSpec) according to the manufacturer's protocol.

    Techniques: Standard Deviation

    Soluble ACE2 (sACE2) activity stratified by age group in sera of (A) 1192 participants 3 months and (B) 345 participants 1 year after SARS‐CoV‐2 exposure and participants (C) without and (D) with evidence of infection 3 months after SARS‐CoV‐2 exposure. Mean and 1 ± times standard deviation are shown in black and individual data for each participant are depicted in gray. p values were calculated using unpaired t ‐tests.

    Journal: Journal of Medical Virology

    Article Title: Elevated Soluble ACE2 Activity in Children and Adults After SARS‐CoV‐2 Exposure Irrespective of Laboratory‐Confirmed Infection

    doi: 10.1002/jmv.70098

    Figure Lengend Snippet: Soluble ACE2 (sACE2) activity stratified by age group in sera of (A) 1192 participants 3 months and (B) 345 participants 1 year after SARS‐CoV‐2 exposure and participants (C) without and (D) with evidence of infection 3 months after SARS‐CoV‐2 exposure. Mean and 1 ± times standard deviation are shown in black and individual data for each participant are depicted in gray. p values were calculated using unpaired t ‐tests.

    Article Snippet: Plasma sACE2 enzyme activity was determined using the commercially available SensoLyte 390 ACE2 activity assay kit (72086; AnaSpec) according to the manufacturer's protocol.

    Techniques: Activity Assay, Infection, Standard Deviation

    (A) Soluble ACE2 (sACE2) activity in sera of 67 exposed participants without prior evidence of SARS‐CoV‐2 infection (seronegative and no positive PCR) 3 months after SARS‐CoV‐2 exposure stratified by SARS‐CoV‐2 specific T‐cell response. (B) Longitudinal sACE2 activity from 22 T‐cell negative participants 3−12 months after SARS‐CoV‐2 exposure. Individual data for each participant are shown in gray. (A) Mean and 1 ± times standard deviation and (B) longitudinal mean are shown in black. p value was calculated using (A) unpaired and (B) paired t ‐test.

    Journal: Journal of Medical Virology

    Article Title: Elevated Soluble ACE2 Activity in Children and Adults After SARS‐CoV‐2 Exposure Irrespective of Laboratory‐Confirmed Infection

    doi: 10.1002/jmv.70098

    Figure Lengend Snippet: (A) Soluble ACE2 (sACE2) activity in sera of 67 exposed participants without prior evidence of SARS‐CoV‐2 infection (seronegative and no positive PCR) 3 months after SARS‐CoV‐2 exposure stratified by SARS‐CoV‐2 specific T‐cell response. (B) Longitudinal sACE2 activity from 22 T‐cell negative participants 3−12 months after SARS‐CoV‐2 exposure. Individual data for each participant are shown in gray. (A) Mean and 1 ± times standard deviation and (B) longitudinal mean are shown in black. p value was calculated using (A) unpaired and (B) paired t ‐test.

    Article Snippet: Plasma sACE2 enzyme activity was determined using the commercially available SensoLyte 390 ACE2 activity assay kit (72086; AnaSpec) according to the manufacturer's protocol.

    Techniques: Activity Assay, Infection, Standard Deviation

    (A) Schematic illustration of in vitro experiments to determine shedding of soluble ACE2 (sACE2) upon exposure to pseudovirus particles bearing a SARS‐CoV‐2 spike protein (SCoV‐2 spike) (created with BioRender.com ). (B) Absolute soluble ACE2 (sACE2) activity and the change in sACE2 (∆sACE2) activity in the supernatant of Calu‐3 (human lung) cells after 16 h of exposure to pseudovirus with (yes) versus without (no) SARS‐CoV‐2 spike. Individual data points for each biologically independent experiment are depicted with black dots connected by lines. For ∆sACE2 activity, the mean and confidence intervals between the experiments are shown. The p ‐value was calculated using a paired t ‐test.

    Journal: Journal of Medical Virology

    Article Title: Elevated Soluble ACE2 Activity in Children and Adults After SARS‐CoV‐2 Exposure Irrespective of Laboratory‐Confirmed Infection

    doi: 10.1002/jmv.70098

    Figure Lengend Snippet: (A) Schematic illustration of in vitro experiments to determine shedding of soluble ACE2 (sACE2) upon exposure to pseudovirus particles bearing a SARS‐CoV‐2 spike protein (SCoV‐2 spike) (created with BioRender.com ). (B) Absolute soluble ACE2 (sACE2) activity and the change in sACE2 (∆sACE2) activity in the supernatant of Calu‐3 (human lung) cells after 16 h of exposure to pseudovirus with (yes) versus without (no) SARS‐CoV‐2 spike. Individual data points for each biologically independent experiment are depicted with black dots connected by lines. For ∆sACE2 activity, the mean and confidence intervals between the experiments are shown. The p ‐value was calculated using a paired t ‐test.

    Article Snippet: Plasma sACE2 enzyme activity was determined using the commercially available SensoLyte 390 ACE2 activity assay kit (72086; AnaSpec) according to the manufacturer's protocol.

    Techniques: In Vitro, Activity Assay

    Inhibition of ACE2 activity by different concentrations on MLN-4760 or HCQ. Graph shows % of inhibition for ACE2 activity in an inhibitory activity in vitro assay using different concentrations of the specific ACE2 blocker MLN-4760 (black circles) and the aminoquinoline HCQ (diamonds). n = 3‐5.

    Journal: BioMed Research International

    Article Title: Characterization of the Modulatory Effect of Hydroxychloroquine on ACE2 Activity: New Insights in relation to COVID-19

    doi: 10.1155/2021/6614000

    Figure Lengend Snippet: Inhibition of ACE2 activity by different concentrations on MLN-4760 or HCQ. Graph shows % of inhibition for ACE2 activity in an inhibitory activity in vitro assay using different concentrations of the specific ACE2 blocker MLN-4760 (black circles) and the aminoquinoline HCQ (diamonds). n = 3‐5.

    Article Snippet: Recombinant Human ACE2 protein and Recombinant Human Coronavirus SARS-CoV-2 Spike Glycoprotein RBD (Active) (ab151852 and ab273065, respectively) were purchased from ABCAM; MLN-4760 (Cat. No.: HY-19414-10) was purchased from https://www.medchemexpress.com/ , and SensoLyte®390 ACE2 Activity Assay Kit (AS-72086) was purchased from https://www.anaspec.com ; HCQ was purchased from a local pharmaceutical provider.

    Techniques: Inhibition, Activity Assay, In Vitro

    Modulation of ACE2 activity by SARS-CoV-2 spike glycoprotein and its interaction with the inhibitors MLN-4760 and HCQ. Enzyme activity was assayed in the presence of SARS-CoV-2 spike protein (SP), ACE2 inhibitor MLN4760 (MLN), aminoquinoline hydroxychloroquine (HCQ), or their combinations. (a) ACE2 activity in presence of HCQ, MLN4760, or its combination was measured in a kinetic assay using the SensoLyte®390 kit. Fluorescence level and linear regression are represented for each reaction. (b) Kinetic assay showing the effect of SP on HCQ inhibition. (c) Quantification of the effect of SP, MLN, and HCQ on ACE2 activity. SP effect on the inhibition of ACE2 produced by (d) MLN and (e) HCQ. (f) Combined effect HCQ and MLN on ACE2 activity. Relevant comparisons are shown within brackets. ∗ P < 0.05. n = 3‐5.

    Journal: BioMed Research International

    Article Title: Characterization of the Modulatory Effect of Hydroxychloroquine on ACE2 Activity: New Insights in relation to COVID-19

    doi: 10.1155/2021/6614000

    Figure Lengend Snippet: Modulation of ACE2 activity by SARS-CoV-2 spike glycoprotein and its interaction with the inhibitors MLN-4760 and HCQ. Enzyme activity was assayed in the presence of SARS-CoV-2 spike protein (SP), ACE2 inhibitor MLN4760 (MLN), aminoquinoline hydroxychloroquine (HCQ), or their combinations. (a) ACE2 activity in presence of HCQ, MLN4760, or its combination was measured in a kinetic assay using the SensoLyte®390 kit. Fluorescence level and linear regression are represented for each reaction. (b) Kinetic assay showing the effect of SP on HCQ inhibition. (c) Quantification of the effect of SP, MLN, and HCQ on ACE2 activity. SP effect on the inhibition of ACE2 produced by (d) MLN and (e) HCQ. (f) Combined effect HCQ and MLN on ACE2 activity. Relevant comparisons are shown within brackets. ∗ P < 0.05. n = 3‐5.

    Article Snippet: Recombinant Human ACE2 protein and Recombinant Human Coronavirus SARS-CoV-2 Spike Glycoprotein RBD (Active) (ab151852 and ab273065, respectively) were purchased from ABCAM; MLN-4760 (Cat. No.: HY-19414-10) was purchased from https://www.medchemexpress.com/ , and SensoLyte®390 ACE2 Activity Assay Kit (AS-72086) was purchased from https://www.anaspec.com ; HCQ was purchased from a local pharmaceutical provider.

    Techniques: Activity Assay, Kinetic Assay, Fluorescence, Inhibition, Produced